T. Rowe Price Associates
JBIO

T. Rowe Price Associates’s Jade Biosciences JBIO Stock Holding History

T. Rowe Price Associates’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$590K Buy
26,546
+3,968
+18% +$82.8K ﹤0.01% 2551
2026
Q1 		$318K Sell
22,578
-2,591
-10% -$37.5K ﹤0.01% 2659
2025
Q4 		$389K Buy
25,169
+8,913
+55% +$105K ﹤0.01% 2504
2025
Q3 		$141K Hold
16,256
– – ﹤0.01% 2865
2025
Q2 		$163K Buy
+16,256
New +$553K ﹤0.01% 2779
2023
Q1 		– Sell
-378
Closed -$387K – 2927
2022
Q4 		$387K Buy
+378
New +$274K ﹤0.01% 2264

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates's JBIO Position: Q2 2026 in Review

T. Rowe Price Associates increased its Jade Biosciences (JBIO) stake by 18% in Q2 2026, buying an estimated $82.8K and bringing the position to 26,546 shares worth $590K. The position accounts for ﹤0.01% of the portfolio, ranked #2551.

T. Rowe Price Associates first reported a position in JBIO in Q4 2022 and has held it in 6 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • T. Rowe Price Associates held 26,546 shares of Jade Biosciences worth $590K as of Q2 2026.
  • T. Rowe Price Associates bought 3,968 Jade Biosciences shares in Q2 2026, an estimated $82.8K.
  • Jade Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2551 holding.
  • T. Rowe Price Associates first reported a position in Jade Biosciences in Q4 2022 and has held it in 6 quarters since.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.